HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on MediWound (NASDAQ:MDWD) and maintained a $26 price target on the stock.
November 22, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on MediWound with a $26 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $26 price target by a reputable analyst could lead to increased investor confidence in MediWound, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100